A Study of Avatrombopag in Adults With Aplastic Anemia Who Did Not Respond to, Cannot Receive, or Had Return of Disease After Standard Treatment
← catalyst calendarNCT07786922 · readout in 673 d
Sponsored by Swedish Orphan Biovitrum (industry) · SOBI.ST — their whole pipeline →. With Sobi, Inc., CMIC Co, Ltd. Japan.
Phase
Phase 2/3
Status
Not yet recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
26estimated
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-26
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-07-31 | estimated | When the study began enrolling |
| Primary completion | 2028-06-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-12-31 | estimated | The whole study's end, after follow-up |
| First posted | 2026-08-26 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-26 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Aplastic Anemia
Intervention
- Drug: Avatrombopag 20 mg Oral Tablet
Primary outcome
what the primary-completion date above is the date OFThe effect of avatrombopag on the proportion of trial participants achieving a hematological response at Week 26 in trial participants diagnosed with AA.
measured at Week 26
Related
SOBI.ST · their whole pipeline
SOBI.ST's other studiesmost recently updated first
- Evaluate Efficacy, Safety and Tolerability, PK and PD of Emapalumab in Children and Adults With MAS in Still's or SLE Phase 3 · Completed
- A Post-authorization Study to Describe the Safety and Efficacy of Emapalumab for the Treatment of pHLH in Treatment Experienced Chinese Patients Phase 4 · Completed
- A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS) Phase 2 · Active, not recruiting
- Pacritinib Effectiveness in Real-world Settings — · Not yet recruiting
- Real-World Effectiveness and Safety of Pegcetacoplan in Patients With C3G or IC-MPG: A Multi-Country Study Phase 4 · Recruiting
Permalink · SOBI.ST's whole pipeline · Catalyst calendar · Every registered study · What changed